论文部分内容阅读
Katz 医生问:美国儿科研究院(AAP)和疾病控制中心的免疫实施委员会(ACIP)最近建议,在2和4月龄时口服2剂脊髓灰质炎疫苗(OPV),随后再分别于18月龄和4～6岁时各加服1剂。然而AAP和ACIP还建议,对于确信具有接触脊髓灰质炎病毒显著危险的地区的儿童,在口服第2剂疫苗后2个月,需给予第3剂疫苗。美国的哪些儿童应于6月龄时接受第3剂疫苗?此法可望增加个体或群体的免疫力程度如何?根据美国目前的脊髓灰质炎流行病学,有何资料提示这种裨益可能具有临床意义?
Dr. Katz asks: The Immunization Implementation Council (ACIP) of the American Academy of Pediatrics (AAP) and Centers for Disease Control recently recommended that two doses of polio vaccine (OPV) be given orally at 2 and 4 months of age, And 4 to 6 years old plus one serving. However, AAP and ACIP also recommend that a third dose of vaccine be given 2 months after oral administration of the second dose of vaccine to children who are convinced that they have a significant risk of contracting poliovirus. Which children in the United States should receive a third dose of vaccine at 6 months of age? Is this law expected to increase the level of immunity of individuals or groups? According to the current polio epidemiology in the United States, what information suggests this benefit may have Clinical significance?